More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Lymphoma Clinical Trials & Research

Anas Younes, Chief of the Lymphoma Service at MSK
MSK’s Vision to Transform Lymphoma Treatment
Anas Younes, Chief of the Lymphoma Service, details MSK’s ambitious strategy for advancing lymphoma therapies.
Learn more

Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.

The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.

Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.

Marginal Zone Lymphoma Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
Follicular Lymphoma Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Untreated (Newly Diagnosed)

Prior Treatment (Relapsed/Refractory)

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

A Phase I Study of SGN-CD19B for Patients with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Craig H. Moskowitz
[Protocol 16-710]

A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]

A Phase IB Study of Buparlisib plus Ibrutinib in Patients with Non-Hodgkin Lymphoma
Connie Lee Batlevi
[Protocol 16-009]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 15-236]

A Phase I/II Study of Lenalidomide plus Obinutuzumab and Atezolizumab Immunotherapy in Patients with Recurrent or Persistent Follicular Lymphoma
M. Lia Palomba
[Protocol 16-799]

A Phase I Study of GSK2857916 in Patients with Recurrent or Persistent Multiple Myeloma
Nikoletta Lendvai
[Protocol 14-105]

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

A Phase II Study of RICE Chemotherapy with and without SGN19 in Patients with Recurrent or Persistent Diffuse B-Cell Lymphoma
Craig H. Moskowitz
[Protocol 16-008]

A Pilot Study of Ibrutinib in Patients with Evidence of Follicular Lymphoma after Initial Treatment
Ariela Noy
[Protocol 16-396]

A Phase I/II Study of E7438 in Patients with Advanced Solid Tumors or B-Cell Lymphomas
Connie Lee Batlevi
[Protocol 16-1002]

A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Lymphoma
Anas Younes
[Protocol 17-073]

A Phase II Study of Pembrolizumab Immunotherapy plus Involved Site Radiation Therapy to Treat Early Recurrent or Persistent Hodgkin Lymphoma
Craig H. Moskowitz
[Protocol 17-054]

A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
Alexander M. Lesokhin
[Protocol 16-1447]

A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
Michael A. Postow
[Protocol 17-006]

Small Lymphocytic Lymphoma (SLL) Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
Diffuse Large B-Cell Lymphoma Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Untreated (Newly Diagnosed)

Prior Treatment (Relapsed/Refractory)

A Phase IB Study of Immunotherapy with Atezolizumab plus Obinutuzumab in Patients with Recurrent or Persistent Lymphoma
M. Lia Palomba
[Protocol 14-220]

A Phase I Study of MT-3724 for the Treatment of Relapsed B-cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-265]

A Phase II Study of RICE Chemotherapy with and without SGN19 in Patients with Recurrent or Persistent Diffuse B-Cell Lymphoma
Craig H. Moskowitz
[Protocol 16-008]

A Phase I Study of SGN-CD19B for Patients with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Craig H. Moskowitz
[Protocol 16-710]

A Phase I/II Study of E7438 in Patients with Advanced Solid Tumors or B-Cell Lymphomas
Connie Lee Batlevi
[Protocol 16-1002]

A Phase IB Study of Buparlisib plus Ibrutinib in Patients with Non-Hodgkin Lymphoma
Connie Lee Batlevi
[Protocol 16-009]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-526]

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase I/II Study of INCB039110 pus Ibrutinib in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Paul A. Hamlin
[Protocol 17-190]

A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Alexander M. Lesokhin
[Protocol 16-1347]

A Phase I Study of Immunotherapy with Genetically Modified T Cells to Treat Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
M. Lia Palomba
[Protocol 15-295]

A Phase I Study of GSK2857916 in Patients with Recurrent or Persistent Multiple Myeloma
Nikoletta Lendvai
[Protocol 14-105]

A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
Alexander M. Lesokhin
[Protocol 16-1447]

A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
Michael A. Postow
[Protocol 17-006]

Hodgkin Lymphoma Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
Mantle Cell Lymphoma Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
Burkitt’s Lymphoma Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Untreated (Newly Diagnosed)

Prior Treatment (Relapsed/Refractory)

Richter’s Transformation Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Prior Treatment (Relapsed/Refractory)

T Cell Lymphoma Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Untreated (Newly Diagnosed)

A Phase I/II Study of Lenalidomide plus Combination Chemotherapy to Treat Newly Diagnosed Stage II-IV Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-515]

Prior Treatment (Relapsed/Refractory)

A Phase I/II Study of Brentuximab Vedotin plus Nivolumab Immunotherapy in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-526]

A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042]

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase I/II Study of Lenalidomide plus Combination Chemotherapy to Treat Newly Diagnosed Stage II-IV Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-515]

A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
Alison J. Moskowitz
[Protocol 16-1542]

A Phase II Study of Romidepsin after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 13-020]

A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-1687]

A Phase I Study of Hu5F9-G4 Immunotherapy in Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-1533]

HIV+ Lymphoma Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
Primary CNS Lymphoma or PTL Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Prior Treatment (Relapsed/Refractory)

Waldenstrom’s Macroglobulinemia Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.
Phase I Trials Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of SGN-CD19B for Patients with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Craig H. Moskowitz
[Protocol 16-710]

A Phase I/II Study of Lenalidomide plus Combination Chemotherapy to Treat Newly Diagnosed Stage II-IV Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-515]

A Phase IB Study of Buparlisib plus Ibrutinib in Patients with Non-Hodgkin Lymphoma
Connie Lee Batlevi
[Protocol 16-009]

A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-1536]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

A Phase I Study of Hu5F9-G4 Immunotherapy in Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-1533]

A Phase IIA Study of ALRN-6924 in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-1687]

A Phase I/II Study of INCB039110 pus Ibrutinib in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Paul A. Hamlin
[Protocol 17-190]

A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
Mark A. Dickson
[Protocol 16-1286]

A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
Alexander M. Lesokhin
[Protocol 16-1447]

A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Alexander M. Lesokhin
[Protocol 16-1347]

A Phase I Study of Oral RGX-104 Immunotherapy for Patients with Recurrent or Persistent Advanced Solid Tumors and Lymphoma
Michael A. Postow
[Protocol 17-006]